Status:
COMPLETED
Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients
Lead Sponsor:
Al-Maarif University College
Conditions:
Head and Neck Cancer
Chronic Periodontitis
Eligibility:
All Genders
28-65 years
Brief Summary
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radi...
Detailed Description
The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. The study en...
Eligibility Criteria
Inclusion
- A pathologically confirmed malignant neoplasm of HNC (derived from epithelial cells).
- Not having received radiation therapy previously.
- No distant metastasis.
- No history of salivary gland surgery (parotid, submandibular, or sublingual).
- A generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability.
Exclusion
- Previous oral disease or salivary gland disease history.
- Definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease.
- Refusal to participate in the study.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 23 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06529588
Start Date
September 1 2022
End Date
October 23 2023
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed A. Al-Kubaisi
Ramadi, Al-Anbar Governorate, Iraq, 31001